Merck's COVID-19 pill to be produced by more than two dozen drugmakers

Medicines Patent Pool, an organization supported by the U.N., announced on Thursday that over two dozen generic drug makers will soon begin producing Merck's COVID-19 pill to make the treatment more accessible in developing countries.

The organization said that 27 generic drug makers would produce the pill for 105 developing countries. Specifically, agreements the companies signed allow them to make both molnupiravir's raw ingredients as well as the final product.

Molnupiravir is the COVID-19 treatment developed by Merck and Ridgeback Therapeutics. For patients with early signs of COVID-19, the pill is believed to cut the hospitalization rates in half.

How the COVID-19 pandemic might age us Nature - Infectious disease, loneliness and stress can affect cellular ageing, making us less healthy and shortening lifespans. Sohn, Emily nature

As the COVID-19 pandemic continues, we might feel we’re ageing faster than before. That’s not as strange as it sounds. Accelerated ageing can result from several factors, some of which have been highlighted by the pandemic. Exposure to infectious diseases, chronic stress and loneliness can all affect the ageing process, exacerbating health conditions and shortening lives.